Morepen Laboratories Limited · NSE:MOREPENLAB
Morepen Laboratories — Q1 FY2026 Earnings Presentation
30 slides from Morepen Laboratories's earnings presentation, Aug 6, 2025
Slide 1: Investor Presentation filing letter to NSE and BSE
Date: 06/08/2025 To, National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (East), Mumbai- 400 051 Dalal Street, Mumbai- 400 001 Symbol: MOREPENLAB Scrip Code: 500288 Subject: Investor Presentation – Q1’ FY26 Dear Sir/ Madam, Please
Slide 2: Q1'FY26 Investor Presentation
Q1'FY26 investor presentation MOREPEN LABORATORIES LIMITED
Slide 3: Safe Harbour
SAFE HARBOUR This investor presentation has been prepared for general information purposes in respect of Morepen Laboratories Limited (“Company”) together with its subsidiary, as applicable (together, with the Company, the “Group”) only, without regard to any specific objectives, suitability, financ
Slide 4: Executive Summary
EXECUTIVE sUmMMaARY
Slide 5: Strongest Quarter Ever in Glucometer Sales – 1 Million+ Units Sold
1 Executive Summary Q1'FY 26 Business overview: mg/dL Strongest Quarter Ever in Glucometer Sales – 1 Million+ Units Sold! ''. ,_,,-, '' ,-,,-,. 1_11: AM '-''-'· '_, • With a solid 15.27 million diabetic patient customer base, the company continues to invest in acquiring new customers and installing
Slide 6: Strengthening Core APIs – Domestic Pivot Pays Off
1 Executive Summary Q1'FY 26 Business overview: Strengthening Core APIs – Domestic Pivot Pays Off • Despite global headwinds, the company has managed to reinforce its market leadership in the key APIs. • Strategic pivoting towards increased sales and marketing efforts in the domestic market to shiel
Slide 7: Q1'FY26 Executive Summary: Business Segments
1 Executive Summary Q1'FY 26 Business Segments: standAlone Medical Devices Pharma Business Point of Care API+Rx 41% 59% Share of Medical Share of Pharma Devices Business
Slide 8: Q1'FY26 Executive Summary: Standalone Revenue
1 Executive Summary Q1'FY 26 standalone revenue: Annual Revenue quarterly Revenue Rs. in Crores Rs. in Crores 2000 389 385 395 1570 400 1550 1500 300 1000 200 500 100 0 0 FY'24 FY'25 Q1'FY25 Q4'FY25 Q1'FY26
Slide 9: Medical Devices
2 Medical devices Q1'FY 26
Slide 10: Medical Devices Market Leadership
2 Medical Devices Q1'FY 26 market leadership: #1 #1 25 yr Market Leaders for Market Leaders for of focused customer Own manufacturing Blood Glucose meters BP Monitors service since 10 years 15m ISO 15 million Meters installed, fully backward integrated All India Distribution ISO-13485 Approved repea
Slide 11: Top Selling Products
2 Medical Devices Q1'FY 26 Top selling Products: Blood Glucose meters BP Monitors Nebulisers 9Bt.f1' :0 Thermometers Ortho supports Stethoscope Pregnancy Kits
Slide 12: Medical Devices Total Revenue
2 Medical Devices Q1'FY 26 Total revenue : Annual Revenue quarterly Revenue Rs. in Crores Rs. in Crores 496 200 500 443 12% 161 400 150 138 16% 300 100 200 50 100 0 0 FY'24 FY'25 Q1'FY25 Q1'FY26
Slide 13: Glucometer Revenue
2 Medical Devices Q1'FY 26 glucometer revenue : no. of Glucometers no. of strips Annual Revenue sold sold Rs. in Crores (lakh) (lakh) 140 129 12 10.63 1400 1320 120 107 21% 10 72% 1200 1171 13% 100 8 1000 80 6.18 800 6 60 600 4 400 40 2 200 20 0 0 0 Q1'FY25 Q1'FY26 Q1'FY25 Q1'FY26 Q1'FY25 Q1'FY26
Slide 14: Glucometer Leadership
2 Medical Devices Q1'FY 26 glucometer Leadeship: 15.3 mn 2.1 bn gluco meters sold Gluco Strips sold Happy customer base Individual tests strips Cumulative YTD numbers
Slide 15: BP Monitor Revenue
2 Medical Devices Q1'FY 26 BP Monitor revenue : no. of BP meters sold Annual Revenue (Lakhs) Rs. in Crores 30 3.5 3.37 3.17 26 25 24 3.0 6% 7% 2.5 20 2.0 15 1.5 10 1.0 0.5 5 0.0 0 Q1'FY25 Q1'FY26 Q1'FY25 Q1'FY26
Slide 16: Digital Assets
2 Medical Devices Q1'FY 26 Digital assets: ....... _ H O U • l'l'NQ'J Your Total Logs Uilolftowo'"'.:c.l i :!0« ;, l0_; £ Take control of your - ■ 24 10 16 . TDLlllllood Q.,.,,oi.,;LC> Toultllood Prn........ L.-, ToUIWliCN \.c,p health and wellness with r 901 1 ~1 1'1'-'•J • r 0 ~v......,.l l1 HlAC
Slide 17: Growth Drivers: Exploring International Markets
2 Medical Devices Q1'FY 26 growth drivers: • Exploring more to International markets: USA Kenya Malasiya • Exhibited in the above new markets, in addition to the regular shows in Thailand, Qatar, Oman, Dubaii
Slide 18: Pharma Business
3 Pharma Business
Slide 19: Total Pharma Revenue
3 Pharma Business Q1'FY 26 Total Pharma revenue : Annual Revenue quarterly Revenue Rs. in Crores Rs. in Crores 300 282 1200 1107 1074 250 250 235 1000 800 200 600 150 400 100 200 50 0 0 FY'24 FY'25 Q1'FY25 Q4'FY25 Q1'FY26
Slide 20: API Product-wise Breakup
3 pHarma Business/API Q1'FY 26 Product-wise breakup: Others Monte 13.1% 13.2% Rosu PRODUCT share 13.1% API revenue split Lorata +Des Q1'FY26 23% Fexo 10.9% Atorva 26.7%
Slide 21: New Products Launched
3 pHarma Business/API Q1'FY 26 New products launched*: Diabetics cardiac Other • Sitagliptin • Apixaban • resmetirom • Linagliptin • Edoxaban • Vonoprazan • Dapagliflozin • rivaroxaban • Vortioxetine • Empagliflozin • Olmesartan • bexpiprazole • SAXAGLIPTIN • ticagrelor • Ertugliflozin • bempedoic a
Slide 22: Unstable Export Scenario: Continent-wise Share
3 pHarma Business/API Q1'FY 26 Unstable export scnario: Continent-wise share S. America USA S. America 3.2% USA 3.4% 12.6% 17% India India 30.5% 30.2% FY 25 Europe Q1 22.6% FY 26 Europe MENA 32.6% 2.9% Asia Asia 28% 16.9%
Slide 23: Region Wise Performance
2 pHarma Business/API Q1'FY 26 region wise performance: Rs. in Crores USA Europe India Asia others 35 35 70 66 67 100 30 70 70 87 26 60 70 20 18 52 62 80 25 50 60 19 58 15 20 40 50 60 11 15 30 40 10 40 35 7 10 30 20 5 5 20 20 10 0 10 0 0 0 Q1'FY25 Q4'FY25 Q1'FY26 Q1'FY25 Q4'FY25 Q1'FY26 0 Q1'FY25 Q4
Slide 24: API Revenue
2 Pharma Business/API Q1'FY 26 API revenue : Annual Revenue quarterly Revenue Rs. in Crores Rs. in Crores 959 958 300 1000 252 250 224 800 205 200 600 150 400 100 200 50 0 0 FY'24 FY'25 Q1'FY25 Q4'FY25 Q1'FY26
Slide 25: Finished Dosages: New Product Lines Being Added
2 pHarma Business/Finished Dosages Q1'FY 26 new product lines being added Rs. in Crores 35 33 / 30 29 26 Formulation sales 25 consistent growth 20 15 C 10 5 0 ,.. Q1'FY25 Q4'FY25 Q1'FY26
Slide 26: Adding 1000 Medical Representatives in 3 Years
2 pHarma Business/RX Q1'FY 26 To Add 1000 Medical representatives in 3 years No. of Medical representatives 1200 1200 340 1000 Medical Representatives 800 as on june 2025 750 600 400 400 400 200 200 Medical Representatives 0 Mar'25 Mar'26 Mar'27 Mar'28 planned by March 26
Slide 27: Top Rx Products
2 pHarma Business/RX Q1'FY 26 top Rx Products Anti infective GastroIntestinal NEW Tr . NEW lnte UdoFix ,~v ~ AciFix,;@i•>> SUSPENSION Multi vitamin Cardio Diabetic ✓ NEW - ,, Ticap---e---n® Apixamore€•~ EmpamoreM•-
Slide 28: Financial Overview
Q1'FY 26 4 financial Overview
Slide 29: Quarterly Performance
4 Financial Overview Q1'FY 26 Quarterly Performance: Rs. in Crores Gross Revenue EBITDA PAT 500 : 430 385 395 400 35 33 300 30 28 25 23 200 20 12 11 15 12 10 8 100 10 8 6 5 4 2 0 0 0 Q4'FY25 (S) Q1'FY26 (S) Q1'FY26(C) Q4'FY25 (S) Q1'FY26 (S) Q1'FY26(C) Q4'FY25 (S) Q1'FY26 (S) Q1'FY26(C) (S)- Standal
Slide 30: Thank You
MOREVEN THANK YOU www.morepen.com
Morepen Laboratories — Q1 FY2026 Earnings Presentation on 6ix